Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BIND

Financiado

Cerrado

Brain Involvement iN Dystrophinopathies

Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy in childhood, with more than 25,000 patients in Europe. It is due to mutations in the DMD gene that preclude the production of the protein dystrophin. In addi... ver más

30/06/2024

UNIVERSITY COLLEGE...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 21 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-06-30

SC1-BHC-01-2019: Understanding causative mechanisms...

I+D

Cerrada hace 6 años

0% 99% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

21 Participantes

UNIVERSITY COLLEGE LONDON

1.73M€ | Lider

UNIVERSITE DE VERSAILLES SAI...

500.20K€ | Participante

CFR

332.66K€ | Participante

GOSH

41.10K€ | Participante

Proyectos interesantes

MAGIC

Medical Technol...

Data Science

7M€ Cerrado

MUMDUPSC

Medical Technol...

Genetics

197K€ Cerrado

SCOPE-DMD

Medical Technol...

Data Science

21M€ Cerrado

ANTES

Medical Technol...

Data Science

100K€ Cerrado

GENOVAR

Medical Technol...

Data Science

1M€ Cerrado

QUESTFORMD

Medical Technol...

Data Science

232K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 54 meses Fecha Inicio: 2019-12-05
Fecha Fin: 2024-06-30

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy in childhood, with more than 25,000 patients in Europe. It is due to mutations in the DMD gene that preclude the production of the protein dystrophin. In addition to the progressive muscle weakness, 50% of affected individuals have debilitating central nervous system (CNS) co-morbidities, including intellectual disability, neurodevelopmental problems encompassing autism, Attention Deficit Hyperactivity Disorder and Obsessive Compulsive Disorder. These co-morbidities are due to the deficiency of multiple dystrophin isoforms in brain whose expression is differentially affected by the site of the DMD mutation. They represent a major obstacle for patients to live a fully independent life. Current therapies do not address these co-morbidities. The postnatal restoration of one dystrophin isoform using genetic therapies in the DMD mouse model improves the neurobehavioral phenotype. This raises the exciting possibility that some of the CNS co-morbidities could improve with genetic therapies in patients. We need to address several knowledge gaps before considering clinical applications of these therapies: i. dystrophin isoforms localisation in the CNS; ii. which of the neurobehavioural features of the dystrophic mice improve after dystrophin restoration, and circuitries involved; iii. deep phenotype patients to define robust outcome measures. This project developed in partnership with advocacy groups, meets gender criteria and offers for the first time insight into how dystrophins’ affect CNS function, and on the reversibility of the DMD CNS co-morbidities, providing essential information to the field of neurodevelopmental disorders, and for other syndromes arising from dystrophin associated proteins. Our efforts to develop novel therapies that can cross the blood brain barrier could be transformative for the field of neurodegeneration and neurodevelopmental disorders.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores